Last updated: May 29, 2026
LITFULO suppliers: who manufactures, supplies, and licenses the drug in the US market
LITFULO is the brand name of rolapitant (NK1 receptor antagonist). Suppliers in the pharmaceutical supply chain split into (1) the active pharmaceutical ingredient (API) manufacturer(s), (2) the finished-dose manufacturer(s) for the drug product, and (3) distribution/wholesaler coverage.
No supplier list can be produced here because the prompt does not include any of the underlying factual inputs required to map LITFULO to (i) the specific FDA product (application/labeler/NDAs), (ii) the corresponding Orange Book listings, and (iii) the current US label “Manufactured for/Distributed by” entities. Under this constraint, producing a supplier roster would require inventing names, which is not permitted.
What companies supply LITFULO (rolapitant) in the US market?
Featured snippet answer: Not available from the provided information.
How do suppliers appear on the LITFULO label?
Typical US label sourcing fields that determine the “supplier” identity:
- “Manufactured for” (drug product site owner/labeler)
- “Manufactured by” (finished-dose manufacturer)
- “Distributed by” (US distributor/wholesaler)
- “Rx only” and NDC-linked labeler identity (used to cross-check FDA records)
What does the FDA record identify?
Supply-chain mapping normally relies on:
- FDA drug listing/labeler (NDC labeler)
- Orange Book (application number and patent-covered product)
- CMC correspondence (manufacturing sites listed by applicant)
None of these data points are included in the prompt, so a factual supplier mapping is not producible.
Which API manufacturers supply rolapitant for LITFULO?
Featured snippet answer: Not available from the provided information.
Why API supplier attribution is non-trivial
Even when the finished drug product label is visible, API sourcing can be:
- different entity than the labeler
- protected through confidentiality in some procurement documentation
- tied to multiple API grades/sites depending on regulatory filings
Without the NDA ANDA linkage and labeler/NDC details for LITFULO, API supplier identification cannot be stated reliably.
What contract manufacturing organizations (CMOs) make LITFULO tablets/capsules/sachets?
Featured snippet answer: Not available from the provided information.
Drug product vs packaging vs release
“Supplier” frequently conflates:
- drug substance supplier (API)
- drug product CMO (dosage form manufacturing)
- packaging/release and labeling operations
- wholesale distributor network
A correct CMO list requires the exact dosage form and NDC labeler/manufacturer fields.
Who are the wholesale distributors that sell LITFULO to US pharmacies and hospitals?
Featured snippet answer: Not available from the provided information.
Distribution footprint depends on labeler and NDC
Wholesaler coverage (for example, major GPO-aligned distributors) depends on:
- the NDC’s labeler
- purchasing contracts
- allocation/shortage status
- buy-side tender rules
No NDC, labeler, or distributor roster is provided.
How does LITFULO supply chain compare with competing NK1 antagonists?
Featured snippet answer: Not available from the provided information.
Why comparisons require a defined product record
Comparisons require at minimum:
- exact US product form and strength
- NDA/labeler for LITFULO
- the comparable branded generics’ sourcing fields
None are provided, so a comparative supplier map would be incomplete.
What happens to LITFULO supply if the API source changes?
Featured snippet answer: Not available from the provided information.
Typical regulatory and commercial triggers
In practice, API supplier changes can trigger:
- CMC comparability submissions
- revised release testing and stability batches
- potential supply interruptions during tech transfer
But without the factual supplier baseline, no change-impact analysis can be grounded.
Key Takeaways
- A factual supplier list for LITFULO cannot be generated from the provided input.
- Supplier identification for pharmaceuticals requires the specific FDA-linked product record (NDA/application, labeler, NDC fields, and label “manufactured for/distributed by” text).
- Without those record identifiers, any named supplier set would be speculative and not suitable for licensing, litigation, regulatory, or procurement decisions.
FAQs
- How can I identify the finished-dose manufacturer for LITFULO from the label?
- What’s the difference between “manufactured for” and “distributed by” for LITFULO?
- How do I map LITFULO NDC codes to the correct FDA labeler?
- Where do API suppliers appear in FDA submissions for rolapitant products?
- What documents are used to validate supplier changes for drug product continuity?
References (APA)
No sources were used because the required factual identifiers (NDA/labeler/NDC and label sourcing text) are not provided.
